Oral drugs inhibiting the VEGF pathway;Les inhibiteurs oraux de la voie du VEGF

Bulletin du Cancer

Volumn 94, Issue SPECIAL, 2007, Pages

  Ropert, Stanislas ^a   Mir, Olivier ^a   Armand, Jean Pierre ^b  

^a Hôpital Cochin ^*

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Inhibitor of VEGF pathway

Indexed keywords

AGURON; AXITINIB; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN RECEPTOR; VATALANIB;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ASTHENIA; CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; HUMAN; KIDNEY CARCINOMA; PROTEINURIA; REVIEW;

ADMINISTRATION, ORAL; ANGIOGENESIS INHIBITORS; ANIMALS; ASTHENIA; BENZENESULFONATES; HUMANS; HYPERTENSION; IMIDAZOLES; INDAZOLES; INDOLES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PHTHALAZINES; PIPERIDINES; PROTEINURIA; PYRIDINES; PYRROLES; QUINAZOLINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34548623753     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2007.0346     Document Type: Review

References (77)

1. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005 ; 438 : 967-74.
2. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989 ; 161 : 851-8.
3. Plouet J, Schilling J, Gospodarowicz D. Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT-20 cells. EMBO J 1989 ; 8 : 3801-6.
4. De Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992 ; 255 : 989-91.
5. Terman BI, Dougher-Vermazen M, Carrion ME, Dimitrov D, Armellino DC, Gospodarowicz D, et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 1992 ; 187 : 1579-86.
6. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993 ; 362 : 841-4.
7. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997 ; 57 : 4593-9.
8. Margolin K, Gordon MS, Holmgren E, Gaudreault J, Novotny W, Fyfe G, et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer : pharmacologic and long-term safety data. J Clin Oncol 2001 ; 19 : 851-6.
9. Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 1994 ; 367 : 576-9.
10. Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases : targets for cancer therapy. Nat Rev Cancer 2004 ; 4 : 361-70.
11. Yaish P, Gazit A, Gilon C, Levitzki A. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science 1988 ; 242 : 933-5.
12. Fry DW, Kraker AJ, McMichael A, Ambroso LA, Nelson JM, Leopold WR, et al. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 1994 ; 265 : 1093-5.
13. Wakeling AE, Barker AJ, Davies DH, Brown DS, Green LR, Cartlidge SA, et al. Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines. Breast Cancer Res Treat 1996 ; 38 : 67-73.
14. Kowanetz M, Ferrara N. Vascular endothelial growth factor signaling pathways : therapeutic perspective. Clin Cancer Res 2006 ; 12 : 5018-22.
15. Nishishita T, Lin PC. Angiopoietin 1, PDGF-B, and TGF-beta gene regulation in endothelial cell and smooth muscle cell interaction. J Cell Biochem 2004 ; 91 : 584-93.
16. Hariawala MD, Horowitz JR, Esakof D, Sheriff DD, Walter DH, Keyt B, et al. VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in porcine hearts. J Surg Res 1996 ; 63 : 77-82.
17. Horowitz JR, Rivard A, van der Zee R, Hariawala M, Sheriff DD, Esakof DD, et al. Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium. Arterioscler Thromb Vasc Biol 1997 ; 17 : 2793-800.
18. Sato K, Wu T, Laham RJ, Johnson RB, Douglas P, Li J, et al. Efficacy of intracoronary or intravenous VEGF 165 in a pig model of chronic myocardial ischemia. J Am Coll Cardiol 2001 ; 37 : 616-23.
19. Malavaud B, Tack I, Jonca F, Praddaude F, Mora F, Ader JL, et al. Activation of Flk-1/KDR mediates angiogenesis but not hypotension. Cardiovasc Res 1997 ; 36 : 276-81.
20. Li B, Ogasawara AK, Yang R, Wei W, He GW, Zioncheck TF, et al. KDR (VEGF receptor 2) is the major mediator for the hypotensive effect of VEGF. Hypertension 2002 ; 39 : 1095-100.
21. Veronese ML, Mosenkis A, Flaherty KT, Gallagher M, Stevenson JP, Townsend RR, et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 2006 ; 24 : 1363-9.
22. Yang R, Ogasawara AK, Zioncheck TF, Ren Z, He GW, DeGuzman GG, et al. Exaggerated hypotensive effect of vascular endothelial growth factor in spontaneously hypertensive rats. Hypertension 2002 ; 39 : 815-20.
23. Humphreys BD, Sharman JP, Henderson JM, Clark JW, Marks PW, Rennke HG, et al. Gemcitabine-associated thrombotic microangiopathy. Cancer 2004 ; 100 : 2664-70.
24. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006 ; 24 : 25-35.
25. Ballermann BJ. Glomerular endothelial cell differentiation. Kidney Int 2005 ; 67 : 1668-71.
26. Sugimoto H, Hamano Y, Charytan D, Cosgrove D, Kieran M, Sudhakar A, et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 2003 ; 278 : 12605-8.
27. Noris M, Perico N, Remuzzi G. Mechanisms of disease : pre-eclampsia. Nat Clin Pract Nephrol 2005 ; 1 : 98-114.
28. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003 ; 111 : 649-58.
29. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006 ; 355 : 992-1005.
30. Roberts WG, Palade GE. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci 1995 ; 108 : 2369-79.
31. Kamba T, Tam BY, Hashizume H, Haskell A, Sennino B, Mancuso MR, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 2006 ; 290 : H560-H576.
32. Dileo P. Hypothyroidism may accompany SU11248 therapy. J Clin Oncol 2005 ; 23 (abstract 16S-3040).
33. Schoeffski P. Sunitinib related hypothyroidism. J Clin Oncol 2006 ; 24 (abstract 18S-3092).
34. Shaheen PE. Thyroid function tests abnormalities during sunitinib treatment. J Clin Oncol 2006 ; 24 (abstract 18S-4605).
35. Ferrara N, Chen H, Davis-Smyth T, Gerber HP, Nguyen TN, Peers D, et al. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat Med 1998 ; 4 : 336-40.
36. Storkebaum E, Lambrechts D, Carmeliet P. VEGF : once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays 2004 ; 26 : 943-54.
37. Glusker P, Recht L, Lane B. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 2006 ; 354 : 980-2.
38. Ozcan C, Wong SJ, Hari P. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 2006 ; 354 : 980-2.
39. Govindarajan R, Adusumilli J, Baxter DL, El Khoueiry A, Harik SI. Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY43-9006. J Clin Oncol 2006 ; 24 : e48.
40. Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996 ; 334 : 494-500.
41. Tam CS, Galanos J, Seymour JF, Pitman AG, Stark RJ, Prince HM. Reversible posterior leukoencephalopathy syndrome complicating cytotoxic chemotherapy for hematologic malignancies. Am J Hematol 2004 ; 77 : 72-6.
42. Tam BY, Wei K, Rudge JS, Hoffman J, Holash J, Park SK, et al. VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis. Nat Med 2006 ; 12 : 793-800.
43. Richard S, Croisille L, Yvart J, Casadeval N, Eschwege P, Aghakhani N, et al. Paradoxical secondary polycythemia in von Hippel-Lindau patients treated with anti-vascular endothelial growth factor receptor therapy. Blood 2002 ; 99 : 3851-3.
44. Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors : pharmacokinetic and clinical results. J Clin Oncol 2005 ; 23 : 5474-83.
45. Kim S. Phase II study of axitinib in patients with advanced thyroid cancer. J Clin Oncol 2006 ; 24 (abstract 18S-5529).
46. Lyons JF, Wilhelm S, Hibner B, Bollag G. Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer 2001 ; 8 : 219-25.
47. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004 ; 64 : 7099-109.
48. Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005 ; 23 : 965-72.
49. Escudier B. Randomized phase III trial of BAY 43-9006 in patients with advanced renal cell carcinoma. J Clin Oncol 2005 ; 23 (abstract 18S-4510).
50. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006 ; 24 : 2505-12.
51. Flaherty KT. Phase I/II trial of BAY 43-9006 in patients with metastatic melanoma. J Clin Oncol 2006 : 23 (abstract 16S-3037).
52. Eisen T. Phase I trial of sorafenib comboned with DTIC in metastatic melanoma patients. J Clin Oncol 2005 : 23 (absttact 16S-7508).
53. Flaherty KT. Phase I/II trial of BAY 43-9006, carboplatin ant paclitaxel in metastatic melanoma. J Clin Oncol 2004 : 22 (abstract 14S-7507).
54. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mu-tations of the BRAF gene in human cancer. Nature 2002 ; 417 : 949-54.
55. Bos JL. Ras oncogenes in human cancer : a review. Cancer Res 1989 ; 49 : 4682-9.
56. Houk BE. pharmacokinetics and efficacy of sunitinib in patients with metastatic renal cell cancer. J Clin Oncol 2006 ; 24 (abstract 18S-4531).
57. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006 ; 24 : 16-24.
58. Motzer RJ. Phase III randomized trial of sunitinib versus IFN-alpha as first line systemic therapy for patients with metastatic renal cell carcinoma. J Clin Oncol 2006 ; 24 (abstract 18S-LBA3).
59. Socinski MA. Efficacy and safety of sunitinib in previously treated advanced NSCLC : multicenter phase II. J Clin Oncol 2006 ; 24 (abstract 18S-7001).
60. Kulke M. Phase II study to evaluate efficacy and safety of SU11298 in patients with unresectable neuroendocrine tumors. J Clin Oncol 2006 ; 23 (abstract 16S-4008).
61. Lenz H. Phase II trial of SU11248 in patients xith mCRC after failue of standard chemotherapy. J Clin Oncol 2006 ; 241.
62. Demetri GD. Phase III trial of SU11248 versus placebo in patients following failure of imatinib for metastatic GIST. J Clin Oncol 2005 ; 23 (abstract 16S-4000).
63. Holden SN, Eckhardt SG, Basser R, de Boer R, Rischin D, Green M, et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol 2005 ; 16 : 1391-7.
64. Natale RB. ZD6474 versus gefitinib in patients with advanced NSCLC : results of randomised phase II. J Clin Oncol 2006 ; 24 (abstract 18S-7000).
65. Heymach JV. Phase II trial of ZD6474 plus docetaxel in patients with previously treated NSCLC. J Clin Oncol 2006 ; 24 (abstract 18S-7016).
66. Heymach JV. Preliminary results of phase II trial : ZD6474 in cmbination with carboplatin and paclitaxel as first line treatment in NSCLC patients. J Clin Oncol 2005 ; 23 (abstract 16S-7102).
67. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002 ; 346 : 92-8.
68. Miller KD, Trigo JM, Wheeler C, Barge A, Rowbottom J, Sledge G, et al. A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin Cancer Res 2005 ; 11 : 3369-76.
69. Hecht JR. Phase III of vatalanib plus Folfox 4 versus Folfox as first line treatment in metastatic CRC. J Clin Oncol 2006 ; 23 (abstract 16S-3).
70. Major P. Pooled analysis of Confirm 1 and Confirm 2. J Clin Oncol 2006 ; 24 (abstract 18S-3529).
71. Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC, Harris AL. Lactate dehydrogenase 5 expression in operable colorectal cancer : strong association with survival and activated vascular endothelial growth factor pathway: a report of the Tumour Angiogenesis Research Group. J Clin Oncol 2006 ; 24 : 4301-8.
72. Gauler TC. Phase II trial of vatalanib as second line therapy in patients with advanced NSCLC. J Clin Oncol 2006 ; 24 (abstract 18S-7195).
73. Conrad C. Phase I/II trial of vatalanib in patients with recurrent GBM. J Clin Oncol 2004 ; 22 (abstract 14S-1512).
74. Schroder W. Phase Ib of vatalanib in combination with paclitaxel and carboplatin in patients with ovarian cancer. J Clin Oncol 2006 ; 24 (abstract 18S-5075).
75. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000 ; 100 : 57-70.
76. Stone EM. A very effective treatment for neovascular macular degeneration. N Engl J Med 2006 ; 355 : 1493-5.
77. Ronnen EA, Kondagunta GV, Ginsberg MS, Russo P, Motzer RJ. Long-term response with sunitinib for metastatic renal cell carcinoma. Urology 2006 ; 68 : 672-80.